
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA HEALTH GROUP INC.

中國醫療集團有限公司

(Carrying on business in Hong Kong as “萬全醫療集團”)
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 08225)

Voluntary Announcement

New Development for the Group's Business

Affiliated companies of CHG China Medical Group (“CHG” or the “Group”) have signed agreements of clinical research and promotion on psychotherapeutic drugs for children respectively with Yueyang New Huada Pharmaceutical Co., Ltd and Shandong Lanuo Pharmaceutical Co., Ltd. The above cooperation will play a strong role in promoting the business development of the Group.

With the release of the Report on Children's Mental Disorders, it turns out that more and more students face the problem of psychological disorders, and 17.5% of the students aged 6-16 have psychological disorders. Many of the top pediatric clinical research centers in China are full, and the medical market demand is huge. In this context, Xixin RWS Center, as a leading clinical research center for mental disorders in China, has reached cooperation respectively with Yueyang New Huada Pharmaceutical Co.,Ltd. and Shandong Lanuo Pharmaceutical Co., Ltd., to jointly promote the research and development and promotion of children's mental psychotherapy drugs.

Through the three core drivers of real-world clinical research RWS, medical big data RWD and artificial intelligence, CHG China Medical Group provides for life sciences "research specialty" CHGmyD service, "drug clinical research" CHGRWS service and reconstruction of "scientific research product promotion" CRS0 service in the trillion drug promotion market. On the basis of curing the two century diseases focusing on brain science and allergy, five specialized brands are built: min anti-sensitivity, psychological spirit, prevention and treatment of stroke, smoking addiction and rare disease ALS.

This cooperation will bring more development opportunities and business expansion spaces for the Group, and promote the innovation and development of the Group in the field of children's psychiatric psychotherapy. At the same time, it will also inject new vitality into the development of China's medical market, and provide

more patients with better quality and more efficient treatment programs and services.

Therefore, it is hereby announced. Due to the huge uncertainty of the market, please consult professionals to invest cautiously.

By order of the Board
China Health Group Inc.
GUO Xia
Chairman

Hong Kong, January 15, 2024

As at the date hereof, the Board comprises two executive Directors, being Mr. GUO Xia and Dr. SONG Xuemei; one non-executive Director, being Ms. ZHANG Li; and three independent non-executive Directors, being Mr. QIU Rui, Dr. NI Binhui and Mr. GUO Tong.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of The Stock Exchange of Hong Kong Limited website at <http://www.hkexnews.hk> for 7 days from the date of its posting. This announcement will also be posted on the Company's website at <http://www.chgi.net>.